Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Stock Information for Spero Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.